Lifeward outlines rehabilitation robotics growth strategy, highlights reimbursement coverage moat
LFWD•Oramed partnership funding support
The Oramed partnership was described as funding support of up to USD 47 million, including a 4% ReWalk royalty over 10 years.
Operating snapshot and pipeline timing
Operating snapshot as of June 30, 2026:
- LTM revenue: USD 21.8 million
- Cash: USD 11 million
- Q2 revenue: USD 6.6 million
Pipeline timing targets:
- AlterG StrideSense in 2027
- Upper-body exoskeleton in 2028
- ReWalk X in early 2029
Growth strategy and reimbursement coverage
Lifeward outlined a strategy to scale its rehabilitation robotics platform, citing reimbursement coverage as a key competitive moat.
